Business Wire

Partikula Appoints Leading Cancer Metabolism Experts to Advisory Board; Extends Its Work On Its Multiple Checkpoint Inhibitors; Adds Seasoned Technical Development Professional ...

SUNRISE, Fla.--(BUSINESS WIRE)--Partikula LLC, a late stage preclinical biotechnology company, today announced the addition of Dr. Matthew Vander Heiden and Dr. Joshua Rabinowitz to the company’s ...
Business Wire

Partikula Reports Positive Results From A Multi-Checkpoint Protein Inhibition Study Of Its First-In-Class Precision Tumor Microenvironment Modifiers (TMEM™)

SUNRISE, Fla.--(BUSINESS WIRE)--Partikula LLC, a preclinical-stage biotechnology company, today announced results from a study designed to assess the ability of its first-in-class compound, KULA101 to ...